Blog

NEW! Download PPMD’s Updated Education Matters Guides for Back-To-School

As the beginning of the school year quickly approaches, PPMD is working to support your family and help you plan for a successful classroom experience, whether it be in-person or virtual. We are thrilled to…

Learn More

PPMD Signs Onto Letter Urging Congress to Protect Immunocompromised Patients During the Pandemic

PPMD joined dozens of patient organizations in a letter to Congress urging them to protect immunocompromised patients during the pandemic. Americans living with compromised immune systems have routinely taken precautions in order to avoid becoming…

Learn More

ICYMI: Lunch & Learn Sessions

ICYMI: Lunch & Learn Sessions As part of this year’s Virtual Annual Conference, PPMD offered two Lunch & Learn Sessions where we were introduced to family assistance programs available to our community and we took…

Learn More

Did You Miss the PPMD Virtual Annual Conference?

Did You Miss the PPMD Virtual Annual Conference? PPMD’s first Virtual Annual Conference was incredible with nearly 2500 families, care providers, researchers, scientists, and industry partners joining us for four days of informative updates on…

Learn More

Join PPMD’s Back-To-School Webinar Series

Join PPMD’s Back-To-School Webinar Series Join us for PPMD’s back-to-school webinar series tackling questions and concerns the community has about both in-person and virtual learning environments. PPMD’s Care Team will be joined by leading experts…

Learn More

PPMD Announces Pediatric Certified Duchenne Care Center, Akron Children’s Hospital

Today Parent Project Muscular Dystrophy (PPMD) announced the expansion of our renowned Certified Duchenne Care Center Program (CDCCP) with the certification of the clinic at Akron Children’s Hospital (Akron Children’s) in Akron, Ohio. Rachel Schrader,…

Learn More

Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold

Tonight at PPMD’s Virtual Annual Conference, Solid Biosciences shared that their IGNITE DMD Phase I/II clinical trial will remain on clinical hold. They also issued a press release here. During this hold, Solid will continue to…

Learn More

Catabasis Shares July 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, which highlights the value of the North Star Ambulatory Assessment in Duchenne. Click here to download the PDF.

Learn More

Vita Therapeutics receives Orphan Drug Designation from FDA

Vita Therapeutics, Inc. recently announced that it received orphan drug designation from the FDA for VTA-110, a novel regenerative therapy for the treatment of Duchenne. VTA-110, is a potential first-in-class allogenic iPSC-based therapy that has…

Learn More

Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy

PPMD was excited to learn at yesterday’s Virtual Annual Conference that Sarepta Therapeutics was granted Fast Track designation for SRP-9001 by the FDA. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding…

Learn More

Join Our Mailing List